Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-08-10
2010-11-09
Cook, Lisa V (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S002000, C435S007100, C436S501000, C436S518000, C436S522000, C422S050000, C422S067000, C530S300000, C530S350000
Reexamination Certificate
active
07829301
ABSTRACT:
The invention relates to identifying agents which have the ability to preferentially inhibit binding to targets such as heparin of the H384 allotypic variant of human complement Factor H, the allotypic variant associated with age-related macular degeneration (AMD), and the non-disease associated form of the same factor (Y384). The targets of interest show differential binding of the two allotypic variants and antagonists thus identified are of interest in developing treatments for AMD.
REFERENCES:
Sjoberg et al. Molecular Immunology, Sep. 2007, vol. 44, No. 16, p. 3988.
Aslam and Perkins, J. Mol. Biol. (2001) 309:1117-1138.
Blackmore et al., J. Immunol. (1996) 157:5422-5427.
Blackmore et al., J. Immunol. (1998) 160:3342-3348.
Day et al., Immunogentics (1998) 27:211-214.
Edwards et al., Science (2005) 308:421-424.
Elward et al., J. Biol. Chem. (2005) 280:36342-36354.
Gardner ot al., Biochem. Biophys. Res. Commun. (1980) 94:61-67.
Gershov et al., J. Exp. Med. (2000) 192:1353-1363.
Giannakis et al., Eur. J. Immunol. (2003) 33:962-969.
Haines et al., Science (2005) 308:419-421.
Heingard et al., J. Biol. Chem. (1986) 261:13866-13872.
Herbert et at., J. Biol. Chem. (2006) 281:16512-16520.
Jarva et al., J. immunol. (1999) 163:3957-3962.
Kardys et al., J. Am. Coil. Cardiol. (2006) 47:1568-1575.
Klein et al., Science (2005) 308:385-389.
Kliffen et al., Arch. Opthalmol. (1996) 114:1009-1014.
Mahoney et al., Anal. Biochern. (2004) 330:123-129.
Mahoney et at., J. Biol. Chem. (2005) 280:27044-27055.
Mullins et al., Eye (2001) 15:390-395.
Mulloy et al., Carbohydr. Res. (1994) 255:1-26.
Mulloy et al., Thromb. Haemost. (2000) 84:1052-1056.
Mulloy and Forster, Glycobiology (2000)10:1147-1156.
Ostrovsky et at., J. Biol. Chern. (2002) 277:2444-2453.
Pavao et al., J. Biol. Chem. (1995) 270:31027-31036.
Ripoche et at., Biochem J. (1988) 249:593-602.
Saito and Munakata, J. Biochern. (2005) 137:225-233.
Schoberg et al., J. Biol. Chem. (2005) 280:32301-32308.
Schonerr et al., J. Vasc. Res. (2004) 41:499-508.
Seddon et al., JAMA (2004) 291:704-710.
Sim et al., Biosci. Rep (1983) 3:1119-1131.
Sim et al., Methods Enzymot. (1993) 223:13-35.
Thomas et al., Thromb. Haemost. (1984) 52:148-152.
Trouw et al., J. Exp. Med. (2005) 201:1937-1948.
White et al., Protein Sci. (2004) 9:2406-2415.
Bishop Paul N.
Blom Anna M.
Clark Simon J.
Day Anthony J.
Heinegard Dick
Cook Lisa V
Lerner David Littenberg Krumholz & Mentlik LLP
The University of Manchester
LandOfFree
Screening assays for binding antagonists of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening assays for binding antagonists of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening assays for binding antagonists of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200293